Influenza a Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018; New Report Launched

DrugPipeline.net has announced the addition of “Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018” research report to their website www.DrugPipeline.net

Logo

Bangalore, India -- (SBWire) -- 03/30/2018 --Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights
Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 10, 1, 29 and 6 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 149 pages "Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018" report covers Introduction, Influenza A Virus, H5N1 Subtype Infections - Overview, Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development, Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment, Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development, Influenza A Virus, H5N1 Subtype Infections - Drug Profiles, Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, Appendix. This report Covered Companies few are - Akshaya Bio Inc, Altimmune Inc, Antigen Express Inc, Aphios Corp, AusBio Ltd, BiondVax Pharmaceuticals Ltd, CEL-SCI Corp, Cocrystal Pharma Inc, Curevac AG, Gemmus Pharma Inc, GlaxoSmithKline Plc, Hemispherx Biopharma Inc.

For more information Visit at: https://www.drugpipeline.net/global-markets-direct/influenza-virus-h5n1-subtype-infections-pipeline-review-h1-2018

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/ebolavirus-infections-ebola-hemorrhagic-fever-pipeline-review-h1-2018

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/neuromyelitis-optica-devic%E2%80%99s-syndrome-pipeline-review-h1-2018

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

Media Relations Contact

Sudeep Chakravarty
Director - Operations
DrugPipeline.net
+1-302-703-9904
https://www.drugpipeline.net/global-markets-direct/influenza-virus-h5n1-subtype-infections-pipeline-review-h1-2018

View this press release online at: http://rwire.com/956816